The future of Advanced Therapies
The Advanced Therapies Congress features speakers from across the entire value chain of cell and gene therapy development; forward-thinking pharma, biotech and startup companies, researchers, clinicians, academics, HTAs, payers, regulators.
New for 2024: Gene Editing Track
Latest advances in gene editing technologies such as CRISPR and Zinc Finger Nucleases as well as the ethical implications and how they are revolutionising gene therapy and gene modified cell therapies.
Latest clinical updates in the immunotherapy and immune-oncology space and exploring how biologic and bispecific therapies are working together with cell and gene therapies to help combat cancer.
With 8 tracks of content, the agenda covers everything from manufacturing, supply chain & logistics, pricing & market access, to developments in key therapeutic areas; cell therapy, gene therapy, gene modified cell therapy, gene editing, stem cells and regenerative medicine, and much more.
At a time of great uncertainty for biotech, and for the world itself, we gather the leaders of biotech, pharma, fast-growing industry start-ups and established solution providers to give us a good indication of where cell and gene therapy is heading next?